261165-05-3

Basic information

• Product Name: (+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID
• Synonyms: Cyclopentanecarboxylicacid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-, (1S,3R)-;(+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID;(+)-(1S,3R)-N-BOC-BETA-HOMOCYCLOLEUCINE;(1S,3R)-(+)-3-(BOC-AMINO)CYCLOPENTANECARBOXYLIC ACID;(1R,3S)-N-TERT-BUTOXYCARBONYL-1-AMINOCYCLOPENTANE-3-CARBOXYLIC ACID;(-)-(1R,3S)-N-ALPHA-T-BUTOXYCARBONYL-1-AMINOCYCLOPENTANE-3-CARBOXYLIC ACID;(-)-(1R,3S)-N-BOC-1-AMINOCYCLOPENTANE-3-CARBOXYLIC ACID;(+)-(1R,3S)-N-BOC-1-AMINOCYCLOPENTANE-3-CARBOXYLIC ACID
• CAS NO: 261165-05-3
• Molecular Formula: C₁₁H₁₉NO₄
• Molecular Weight: 229.27
• Product Categories: Unusual amino acids;API intermediates;Beta-Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 261165-05-3.mol
• Article Data: 2

Chemical Properties

• Melting Point: 35-49 °C
• Boiling Point: 371.18°C (rough estimate)
• Flash Point: 185.1 °C
• Appearance: White/Powder or Chunks
• Density: 1.1482 (rough estimate)
• Vapor Pressure: 6.55E-07mmHg at 25°C
• Refractive Index: 1.4490 (estimate)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: slightly sol. in Methanol
• PKA: 4.62±0.40(Predicted)
• CAS DataBase Reference: (+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID(261165-05-3)
• EPA Substance Registry System: (+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID(261165-05-3)

Safety Data

• Hazard Codes: Xi
• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 261165-05-3(Hazardous Substances Data)

Usage

Description

(+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID is a chiral compound with a specific stereochemistry, featuring a cyclopentane ring and an N-BOC (tert-butyloxycarbonyl) protecting group. (+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID is a key intermediate in the synthesis of various pharmaceuticals and bioactive molecules, particularly those targeting the central nervous system.

Uses

Used in Pharmaceutical Industry:
(+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID is used as a reagent for the synthesis of 3-substituted aminocyclopentanes, which are potent NR2B subtype-selective NMDA antagonists. These antagonists are being developed for the treatment of neuropathic pain and Parkinson's disease, as they can modulate the activity of the NMDA receptor, a key player in neuronal function and synaptic plasticity.
Additionally, due to its unique structure and properties, (+)-(1S,3R)-N-BOC-3-AMINOCYCLOPENTANECARBOXYLIC ACID may also be utilized in other applications within the pharmaceutical industry, such as the development of novel drugs targeting different receptors or enzymes, or as a building block for the creation of complex organic molecules with potential therapeutic effects.

InChI:InChI=1/C11H19NO4/c1-11(2,3)16-10(15)12-8-5-4-7(6-8)9(13)14/h7-8H,4-6H2,1-3H3,(H,12,15)(H,13,14)/p-1/t7-,8+/m0/s1

Upstream product

• 21472-89-9 1-azabicyclo[2.2.1]heptan-3-one 
• 1203306-05-1 cis-3-aminocyclopentanecarboxylic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 774212-79-2 ((1R,3S)-3-benzyloxycarbonylamino-cyclopentyl)-carbamic acid tert-butyl ester 
• 489446-72-2 (1R,3R)-3-tert-butoxycarbonylaminocyclopentanecarboxylic acid methyl ester 
• 625126-75-2 benzyl (1S,3R)-3-amino-1-isopropylcyclopentanecarboxylate hydrochloride 
• 625128-83-8 C₂₁H₃₁NO₄ 
• 625098-82-0 C₂₃H₃₀F₃NO₄ 
• 765297-57-2 C₁₃H₁₇NO₂*ClH 
• 625098-81-9 C₂₁H₃₁NO₃ 
• 625098-78-4 benzyl (1S,3R)-3-[(diphenylmethylene)amino]cyclopentanecarboxylate 
• 1203306-05-1 (1S,3R)-3-aminocyclopentanecarboxylic acid hydrochloride salt 
• 1594129-52-8 (1S,3R)-3-amino-N-((S)-1-(4-((R)-1-(4-(cyclopropylmethoxy)phenyl)pyrrolidin-3-yloxy)phenyl)ethylcyclopentyl)carboxamide 

Relevant articles and documents

Inhibitors of protein kinases

Compounds of general Formula (I): wherein R1, R2, R3, Ra, A, B and x are as defined herein are inhibitors of protein kinases in particular members of the cyclin-dependent kinase family and/or the glycogen synthase kinase 3 family and are useful in preventing and/or treating any type of pain, inflammatory disorders, cancer, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases, metabolic disorders, renal diseases, neurologic and neuropsychiatric diseases and neurodegenerative diseases.